PE20161030A1 - Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores - Google Patents
Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladoresInfo
- Publication number
- PE20161030A1 PE20161030A1 PE2016000720A PE2016000720A PE20161030A1 PE 20161030 A1 PE20161030 A1 PE 20161030A1 PE 2016000720 A PE2016000720 A PE 2016000720A PE 2016000720 A PE2016000720 A PE 2016000720A PE 20161030 A1 PE20161030 A1 PE 20161030A1
- Authority
- PE
- Peru
- Prior art keywords
- formula
- acetylase
- combinations
- alkyl
- immunomodulating drugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Se refiere a una combinacion farmaceutica que comprende un inhibidor especifico de histona deacetilasa 6 (HDAC 6) y un farmaco inmunomodulador (Imid), donde el inhibidor de HDAC6 puede ser de formula I o II y el farmaco Imid es de formula III. En los compuestos de formula I, el anillo B es arilo o heteroarilo, R1 es un arilo o heteroarilo sustituido y R es H o alquilo C1-C6; en la formula II, Rx y Ry junto con el carbono al cual estan unidos forman un ciclopropilo, ciclobutilo, ciclopentilo, entre otros, cada RA es alquilo C1-C6, alcoxi C1-C6, entre otros y m es 0 o 1; y en la formula III, X e Y son C=O, el otro X e Y son CH2 o C=0, y R2 es H o alquilo C1-C6. Dicha combinacion es util en el tratamiento de linfomas
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361911086P | 2013-12-03 | 2013-12-03 | |
US201462061368P | 2014-10-08 | 2014-10-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20161030A1 true PE20161030A1 (es) | 2016-11-06 |
Family
ID=53264136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016000720A PE20161030A1 (es) | 2013-12-03 | 2014-12-03 | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores |
Country Status (17)
Country | Link |
---|---|
US (1) | US9949972B2 (es) |
EP (1) | EP3076973B1 (es) |
JP (1) | JP6535670B2 (es) |
KR (1) | KR20160092018A (es) |
CN (1) | CN105939716A (es) |
AU (1) | AU2014360544A1 (es) |
BR (1) | BR112016012561A2 (es) |
CA (1) | CA2932411A1 (es) |
CL (1) | CL2016001358A1 (es) |
CR (1) | CR20160308A (es) |
EA (1) | EA201691155A1 (es) |
ES (1) | ES2806258T3 (es) |
IL (1) | IL245926A0 (es) |
MX (1) | MX2016007251A (es) |
PE (1) | PE20161030A1 (es) |
PH (1) | PH12016501015A1 (es) |
WO (1) | WO2015084905A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE030679T2 (en) * | 2010-01-22 | 2017-05-29 | Acetylon Pharmaceuticals Inc | Reverse amide compounds as protein deacetylase inhibitors and methods of use |
CN107011270A (zh) | 2010-11-16 | 2017-08-04 | 阿塞蒂隆制药公司 | 作为蛋白质去乙酰化酶抑制剂的嘧啶羟基酰胺化合物和其使用方法 |
EP2839037B1 (en) | 2012-04-19 | 2018-12-26 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
EP3054952B1 (en) * | 2013-10-08 | 2022-10-26 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer |
WO2015054474A1 (en) * | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
JP2016534069A (ja) | 2013-10-24 | 2016-11-04 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Hdac6阻害剤での多嚢胞性疾患の治療 |
JP6535670B2 (ja) | 2013-12-03 | 2019-06-26 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | ヒストンデアセチラーゼ阻害剤と免疫調節薬の組合せ |
US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
KR20170044097A (ko) | 2014-07-07 | 2017-04-24 | 에이스틸론 파마수티컬스 인코포레이티드 | 히스톤 탈아세틸화효소 저해제에 의한 백혈병의 치료 |
CA2969790A1 (en) | 2014-12-05 | 2016-06-09 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine |
MX2017007623A (es) | 2014-12-12 | 2018-09-26 | Regenacy Pharmaceuticals Llc | Derivados de piperidina como inhibidores de hdac1/2. |
US10464906B2 (en) | 2015-06-08 | 2019-11-05 | Acetylon Pharmaceuticals, Inc. | Crystalline forms of a histone deacetylase inhibitor |
ES2769255T3 (es) | 2015-06-08 | 2020-06-25 | Acetylon Pharmaceuticals Inc | Métodos para fabricar inhibidores de la proteína desacetilasa |
JP2019515909A (ja) | 2016-04-19 | 2019-06-13 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物 |
EP3468559B1 (en) * | 2016-06-09 | 2023-11-22 | Dana Farber Cancer Institute, Inc. | Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors |
US11324744B2 (en) | 2016-08-08 | 2022-05-10 | Acetylon Pharmaceuticals Inc. | Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies |
PL3535275T3 (pl) * | 2016-11-04 | 2022-10-24 | Acetylon Pharmaceuticals, Inc. | Kombinacje farmaceutyczne zawierające inhibitor deacetylazy histonowej i inhibitor BCL-2 oraz sposoby ich stosowania |
WO2018098168A1 (en) * | 2016-11-23 | 2018-05-31 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (pd-l1) inhibitor and methods of use thereof |
EP3544612A4 (en) * | 2016-11-23 | 2020-05-13 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3549633A (en) | 1968-11-20 | 1970-12-22 | Merck & Co Inc | Process for preparation of 1-h-imidazo (4,5-b)pyrazin-2-ones |
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
EP2070920B8 (en) | 1996-07-24 | 2011-04-27 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
JP2003528074A (ja) | 2000-03-24 | 2003-09-24 | メチルジーン インコーポレイテッド | ヒストン脱アセチル化酵素の阻害剤 |
DE60130799T2 (de) * | 2000-11-30 | 2008-07-17 | Children's Medical Center Corp., Boston | Synthese von 4-aminothalidomid enantiomeren |
JPWO2002074298A1 (ja) | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Il−6産生阻害剤 |
US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
CN1582277A (zh) | 2001-11-01 | 2005-02-16 | 詹森药业有限公司 | 用作糖原合酶激酶3β抑制剂的酰胺衍生物 |
PL214279B1 (pl) | 2002-03-13 | 2013-07-31 | Janssen Pharmaceutica Nv | Pochodna sulfonyloaminowa, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania |
EP1485099B1 (en) | 2002-03-13 | 2010-07-07 | Janssen Pharmaceutica N.V. | Inhibitors of histone deacetylase |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
PE20040801A1 (es) | 2002-12-12 | 2004-11-25 | Hoffmann La Roche | Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa |
WO2004082638A2 (en) | 2003-03-17 | 2004-09-30 | Syrrx, Inc. | Histone deacetylase inhibitors |
ES2279395T3 (es) | 2003-07-24 | 2007-08-16 | Basf Aktiengesellschaft | Pirimidinas 2-substituidas. |
NZ545864A (en) | 2003-09-22 | 2009-12-24 | S Bio Pte Ltd | Benzimidazole derivates: preparation and pharmaceutical applications |
EP1663953A1 (en) | 2003-09-24 | 2006-06-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
EP1745022B1 (en) | 2004-04-05 | 2014-08-13 | Aton Pharma, Inc. | Histone deacetylase inhibitor prodrugs |
AU2006226861B2 (en) | 2005-03-22 | 2012-08-16 | Dana-Farber Cancer Institute, Inc. | Treatment of protein degradation disorders |
GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
WO2007022408A2 (en) | 2005-08-18 | 2007-02-22 | Merck & Co., Inc. | Combination methods of saha and targretin for treating cancer |
JP2009509923A (ja) | 2005-08-26 | 2009-03-12 | メシルジーン、インコーポレイテッド | ヒストンデアセチラーゼのベンゾジアゼピン及びベンゾピペラジン類似体阻害薬 |
EP1950208B1 (en) | 2005-11-01 | 2012-05-02 | Sumitomo Chemical Company, Limited | Process for producing 6,6-dimethyl-3-oxabicyclo[3.1.0]hexan-2-one |
US7750155B2 (en) | 2006-02-07 | 2010-07-06 | Astellas Pharma Inc. | Pyrazinyl hydroxyacrylamide compounds having an inhibitory effect on the activity of histone deacetylase |
JP5441416B2 (ja) | 2006-02-14 | 2014-03-12 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 二官能性ヒストンデアセチラーゼインヒビター |
EP2019674B1 (en) | 2006-05-03 | 2016-11-23 | The President and Fellows of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
US20100278782A1 (en) | 2006-06-12 | 2010-11-04 | Vrije Universiteit Brussel | Differentiation of rat liver epithelial cells into hepatocyte-like cells |
ES2288802B1 (es) | 2006-07-07 | 2008-12-16 | Universidad De Granada | Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas. |
SG174790A1 (en) | 2006-09-11 | 2011-10-28 | Curis Inc | Tyrosine kinase inhibitors containing a zinc binding moiety |
SI2343286T1 (sl) | 2006-10-28 | 2015-05-29 | Methylgene Inc. | Derivati dibenzo(b,f)(1,4) oksazepina kot inhibitorji histonske deacetilaze |
WO2008102348A1 (en) | 2007-02-21 | 2008-08-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Alpha-halo- and alpha-alkyl-cyclopropylcarboxy compounds and uses thereof |
US20100098657A1 (en) | 2007-12-27 | 2010-04-22 | Schafer Peter H | Method of Treating Cancer with Immunomodulatory Compounds and IgG |
EP2255818B1 (en) | 2008-02-19 | 2018-08-22 | Earnest Medicine Co., Ltd. | Oral or enteral composition useful for recovery of physical functions |
WO2009137503A1 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Hdac inhibitors and uses thereof |
US20110288070A1 (en) | 2008-05-05 | 2011-11-24 | ROGERS Kathryn | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
AU2009271019A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
CA2731730C (en) | 2008-07-23 | 2017-06-13 | President And Fellows Of Harvard College | Deacetylase inhibitors and uses thereof |
MX2011007326A (es) | 2009-01-08 | 2011-10-19 | Curis Inc | Inhibidores de fosfoinositida 3-quinasa con una porcion de enlace de cinc. |
WO2010131922A2 (en) | 2009-05-15 | 2010-11-18 | Korea Research Institute Of Chemical Technology | Amide compound, preparation method thereof and pharmaceutical composition comprising same |
CA2768466C (en) | 2009-07-22 | 2018-08-14 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
US8716344B2 (en) | 2009-08-11 | 2014-05-06 | President And Fellows Of Harvard College | Class- and isoform-specific HDAC inhibitors and uses thereof |
US20130040998A1 (en) | 2010-01-08 | 2013-02-14 | Dana-Farber Cancer Institute, Inc. | Fluorinated hdac inhibitors and uses thereof |
HUE030679T2 (en) | 2010-01-22 | 2017-05-29 | Acetylon Pharmaceuticals Inc | Reverse amide compounds as protein deacetylase inhibitors and methods of use |
US20110280849A1 (en) | 2010-03-26 | 2011-11-17 | Anthrogenesis Corporation | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds |
AU2011255281A1 (en) | 2010-05-21 | 2013-01-10 | Sloan-Kettering Institute For Cancer Research | Selective HDAC inhibitors |
WO2012018499A2 (en) | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
CN107011270A (zh) * | 2010-11-16 | 2017-08-04 | 阿塞蒂隆制药公司 | 作为蛋白质去乙酰化酶抑制剂的嘧啶羟基酰胺化合物和其使用方法 |
EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
US9512083B2 (en) | 2011-07-20 | 2016-12-06 | The General Hospital Corporation | Histone deacetylase 6 selective inhibitors for the treatment of bone disease |
HUE029687T2 (en) * | 2011-09-19 | 2017-03-28 | Sigma Tau Ind Farmaceuti | New effective HDAC inhibitor thio derivatives and their use as medicaments |
EP2839037B1 (en) | 2012-04-19 | 2018-12-26 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
JP2015533173A (ja) | 2012-10-12 | 2015-11-19 | トラスティース・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | タンパク質脱アセチル化酵素阻害剤としてのピリミジンヒドロキシアミド化合物およびその使用方法 |
US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
US9096549B2 (en) | 2013-02-01 | 2015-08-04 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
WO2014197471A1 (en) | 2013-06-03 | 2014-12-11 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase ( hdac) biomarkers in multiple myeloma |
EP3054952B1 (en) | 2013-10-08 | 2022-10-26 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer |
WO2015054474A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
WO2015054197A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma |
JP6584391B2 (ja) | 2013-10-10 | 2019-10-02 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | 非ホジキンリンパ腫を治療するための、hdac阻害剤単独またはpi3k阻害剤との組み合わせ |
CN105722507A (zh) | 2013-10-11 | 2016-06-29 | 埃斯泰隆制药公司 | 组蛋白脱乙酰酶抑制剂与免疫调节药物的组合 |
JP2016534069A (ja) | 2013-10-24 | 2016-11-04 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Hdac6阻害剤での多嚢胞性疾患の治療 |
JP6535670B2 (ja) | 2013-12-03 | 2019-06-26 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | ヒストンデアセチラーゼ阻害剤と免疫調節薬の組合せ |
JP7017309B2 (ja) | 2013-12-20 | 2022-02-08 | アセチロン ファーマシューティカルズ インコーポレイテッド | 多発性骨髄腫におけるヒストン脱アセチル化酵素6(hdac6)バイオマーカー |
US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
US20150359794A1 (en) | 2014-06-13 | 2015-12-17 | Buck Institute For Research On Aging | Impairment of the large ribosomal subunit protein rpl24 by depletion or acetylation |
KR20170044097A (ko) | 2014-07-07 | 2017-04-24 | 에이스틸론 파마수티컬스 인코포레이티드 | 히스톤 탈아세틸화효소 저해제에 의한 백혈병의 치료 |
US20160137630A1 (en) | 2014-10-08 | 2016-05-19 | Acetylon Pharmaceuticals, Inc. | Induction of gata2 by hdac1 and hdac2 inhibitors |
US20160158231A1 (en) | 2014-12-05 | 2016-06-09 | Vib Vzw | Pyrimidine hydroxy amide compounds for treating peripheral neuropathy |
CA2969790A1 (en) | 2014-12-05 | 2016-06-09 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine |
MX2017007623A (es) | 2014-12-12 | 2018-09-26 | Regenacy Pharmaceuticals Llc | Derivados de piperidina como inhibidores de hdac1/2. |
US9713375B1 (en) | 2015-02-26 | 2017-07-25 | Brett Einar Rahm | Collapsible portable table |
-
2014
- 2014-12-03 JP JP2016536157A patent/JP6535670B2/ja active Active
- 2014-12-03 CN CN201480074711.1A patent/CN105939716A/zh active Pending
- 2014-12-03 CR CR20160308A patent/CR20160308A/es unknown
- 2014-12-03 AU AU2014360544A patent/AU2014360544A1/en not_active Abandoned
- 2014-12-03 CA CA2932411A patent/CA2932411A1/en not_active Abandoned
- 2014-12-03 WO PCT/US2014/068263 patent/WO2015084905A1/en active Application Filing
- 2014-12-03 US US14/558,941 patent/US9949972B2/en active Active
- 2014-12-03 PE PE2016000720A patent/PE20161030A1/es not_active Application Discontinuation
- 2014-12-03 BR BR112016012561A patent/BR112016012561A2/pt not_active Application Discontinuation
- 2014-12-03 ES ES14867332T patent/ES2806258T3/es active Active
- 2014-12-03 EP EP14867332.0A patent/EP3076973B1/en active Active
- 2014-12-03 KR KR1020167017811A patent/KR20160092018A/ko not_active Application Discontinuation
- 2014-12-03 EA EA201691155A patent/EA201691155A1/ru unknown
- 2014-12-03 MX MX2016007251A patent/MX2016007251A/es unknown
-
2016
- 2016-05-30 PH PH12016501015A patent/PH12016501015A1/en unknown
- 2016-05-30 IL IL245926A patent/IL245926A0/en unknown
- 2016-06-03 CL CL2016001358A patent/CL2016001358A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
PH12016501015A1 (en) | 2016-07-04 |
CL2016001358A1 (es) | 2017-02-10 |
US9949972B2 (en) | 2018-04-24 |
BR112016012561A2 (pt) | 2017-08-08 |
CA2932411A1 (en) | 2015-06-11 |
JP2016539140A (ja) | 2016-12-15 |
US20150150871A1 (en) | 2015-06-04 |
EA201691155A1 (ru) | 2016-09-30 |
CN105939716A (zh) | 2016-09-14 |
CR20160308A (es) | 2016-11-08 |
EP3076973B1 (en) | 2020-04-29 |
EP3076973A4 (en) | 2017-08-30 |
EP3076973A1 (en) | 2016-10-12 |
IL245926A0 (en) | 2016-07-31 |
MX2016007251A (es) | 2016-09-07 |
AU2014360544A1 (en) | 2016-07-21 |
JP6535670B2 (ja) | 2019-06-26 |
WO2015084905A1 (en) | 2015-06-11 |
ES2806258T3 (es) | 2021-02-17 |
KR20160092018A (ko) | 2016-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20161030A1 (es) | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores | |
CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
NZ714283A (en) | Novel histone deacetylase inhibitors | |
PE20161342A1 (es) | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores | |
ECSP16076566A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4 | |
EA201690848A1 (ru) | Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4 | |
PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
EA201690598A1 (ru) | Аминогетероарил бензамиды в качестве ингибиторов киназы | |
EA201591491A1 (ru) | Соединения тетрагидропирролотиазина | |
AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
EA201591632A1 (ru) | Цитотоксические и антимитотические соединения и способы их применения | |
CY1121677T1 (el) | Ενωσεις διμεθυλοβενζοϊκου οξεος | |
EA201300200A1 (ru) | N-((6-аминопиридин-3-ил)метил)гетероарилкарбоксамиды в качестве ингибиторов калликреина в плазме | |
PE20140302A1 (es) | Inhibidores del virus de la hepatitis c | |
PE20141202A1 (es) | Compuesto de ciclopropanoamina | |
MA40170A (fr) | Dérivés hétérocycliques de morphinan et leur utilisation | |
RS54730B1 (sr) | Inhibitori beta sekretaze | |
CR20140494A (es) | Inhibidores de dgat1 de eter ciclico de cabeza de puente | |
AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
TR201906325T4 (tr) | Tetrazolon sübstitüeli dihidropiridinon MGAT2 inhibitörleri. | |
EA201592268A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 | |
AR094921A1 (es) | Derivados de 2-acilaminotiazol o su sal | |
MX2017005422A (es) | Inhibidores de histona desacetilasa y sus usos en terapia. | |
RS54716B1 (en) | HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS | |
EA201692300A1 (ru) | Производные карбоксамида |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |